NRC Health Q2 TRCV up 11% to $151.9M; adj. EPS $0.31 vs. GAAP loss ($0.15)

NRC HEALTH

Total revenue $35.4M, up 4% YoY; GAAP net loss ($3.3M) vs. adjusted net income $6.9M.
Adjusted EBITDA $9.4M (27% of revenue); free cash flow $0.1M after $2.9M cash payment for accelerated vesting.
TRCV $151.9M, up 11% YoY; strongest bookings for The Governance Institute in seven years.
GAAP diluted EPS ($0.15); adjusted diluted EPS $0.31 on 22.0M shares.
CEO cites double-digit TRCV growth, strong go-to-market execution, and product innovation commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.